Aileron Therapeutics Appoints Kathryn Gregory as Chief ... Rosana Kapeller has over 15 years leadership experience in the biotechnology industry. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations . As of December 15th, there was short interest totalling 279,900 shares, a drop of 54.0% from the November 30th total of 608,600 shares. ALRN-6924 is administered prior to chemotherapy to protect healthy normal cells from negative side effects. Huw M. Nash Net Worth, Biography & Insider Trading HistoryALRN - Stock Quotes for Aileron, NASDAQ: ALRN Stock Price ... From 2005 to 2009, Dr. Kapeller led the development of Aileron's "Stapled Peptide" technology and the first stapled-peptide development candidate. Aileron Therapeutics, Inc. (NASDAQ:ALRN) was the recipient of a significant drop in short interest in December. Joe is also currently the Managing Director of stet vision LLC. Aileron Therapeutics (ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, is pleased to announce that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will provide a company overview and business update at the H.C. Wainwright BIOCONNECT Conference, which will be held virtually January 10th 12th . The move came on solid volume too with far more shares changing hands than in . The average ALRN stock price target is 3.500 with a high estimate of 5.00 and a low estimate of 2.000. Rome Therapeutics, Inc. develops novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome-vast stretches of uncharted genetic materials. January 6-7, 2022 webconference. He is a Senior Advisor at General Atlantic global growth equity. Boston, Massachusetts 02110 (617) 995-0900 NOTICE OF 2021 ANNUAL MEETING OF STOCKHOLDERS . PITTSBURGH, January 05, 2022--Peptilogics, a biotech company that engineers peptide therapeutics to improve the treatment landscape for patients with life-threatening diseases, today announced that the company received an award from the Cystic Fibrosis Foundation. Aileron Therapeutics is a biopharmaceutical company that develops a class of drugs called Stapled Peptides. Koç's founder, Vehbi Koç, built his corporate empire on the back of the state orchestrated marginalisation of Turkey's Armenians, and other non-Muslim communities. Approximately half of CNL patients also have mutations in SET binding protein 1 ( SETBP1) . During the last session, Aileron Therapeutics Inc. (NASDAQ:ALRN)'s traded shares were 0.51 million, with the beta value of the company hitting 2.59. Clinical Trials - Phase 3. He started with To Be Held on June 15, 2021 He is a current recipient of an Outstanding Investigator Award from the National Cancer Institute. Gain Therapeutics is redefining drug discovery with its SEE-Tx™ target identification platform. He is the Founder and President of JPL Biotech, a biopharma/pharmaceutical consulting firm, and serves on the Board of Directors of Pacira Pharmaceuticals, Inc. AILERON THERAPEUTICS, INC. 285 Summer Street, Suite 101 . Aileron Therapeutics, and the Thomson Reuters Founders Share Co. Ltd. In 2010, Aileron Therapeutics signed a $40 million deal with Roche to excecute on multi drug targets.. ALRN-6924, our first-in-class MDM2/MDMX dual inhibitor, is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. Dr. Geraghty was a founder of Back Bay Strategies and held multiple positions at Kendall Strategies, Feinstein Kean Healthcare, and Genzyme Corp. The ALRN share's 52-week high This system gives you practical tools and proven best practices that you can put into action. Nine Square Therapeutics, a San Francisco, CA-based developer of novel therapies for movement disorders, is launching with $50m in . On average, Aileron Therapeutics Inc executives and independent directors trade stock every 63 days with the average trade being worth of $238,840. 2 brokers have issued 12 month price targets for Aileron Therapeutics' shares. Bringing a unique perspective and tech experience to the senior living industry, David . Joe Yanchik is the President and Chief Executive Officer of Aileron Therapeutics (Cambridge, MA) that he helped to found in June of 2005. Aileron lead oncology program entered clinical . Mr. von Rickenbach was co-Founder, Chairman & CEO of PAREXEL International Corporation. Aileron Therapeutics Announces Changes to Management . Prior to Stoke, Huw was a co-founder and vice president of corporate development for Aileron Therapeutics. Aileron Therapeutics is a clinical stage company developing a novel medicine, ALRN-6924, to improve the outcomes and the quality of life of cancer patients. DENNIS ZALLER, Ph.D. Chief Scientific Officer He also is the inventor of the drugs ALRN-6924 (Aileron) and Iclusig® (Ariad/Takeda). Homepage Membership Levels General Discussion Complete Stock List Value Conference The book Podcast Membership Data Coverage Founder's Message Free Trial Screeners GuruFocus Screeners This suggests a possible upside of 550.4% from the stock's current price. is an SAB member of Aileron Therapeutics, Therapy Architects (ALLCRON), Cepheid, Vivid Biosciences, Celgene, RUNX1 Research Program, Novartis, Gilead Sciences (inactive), Monojul (inactive); is an SAB member and holds stock in Aptose Biosciences, Blueprint Medicines, EnLiven Therapeutics, Iterion Therapeutics, Third . Aileron Therapeutics Inc a clinical-stage biopharmaceutical company. The award will support preclinical research in a new class of engineered antibacterial peptides intended to serve as the first line . Joe von Rickenbach. The company was founded by Rosana Kapeller and is headquartered in Cambridge, MA. Dr. Sawyer is head of drug discovery at Courage. Created with Highcharts 7.1.1. chief executive officer and co-founder of . Joe von Rickenbach is a Senior Advisor at General Atlantic, providing strategic support and advice to the firm's investment teams and portfolio companies in the Life Sciences sector. A copy of our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as filed with the Securities and Exchange Commission, or SEC, except for exhibits, will be furnished without charge to any stockholder upon written or oral request to Aileron Therapeutics, Inc., 490 Arsenal Way, Suite 210, Watertown, Massachusetts 02472 or by . July 5, 2020 By FinSMEs. USA. Colony stimulating factor 3 receptor ( CSF3R ) mutations lead to JAK pathway activation and are the molecular hallmark of chronic neutrophilic leukemia (CNL). As you learn and implement the DOC System, a team of coaches, advisors, facilitators, peers, and allies will support and challenge you along your . The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations . Verdine co-founded a number of biotechnology companies including Enanta Pharmaceuticals, Inc. Aileron Therapeutics, Tokai Pharmaceuticals, Ontorii Pharmaceuticals and Eleven Biotherapeutics. Aileron Therapeutics (NASDAQ:ALRN) is a clinical-stage biopharmaceutical company that is discovering and developing novel medicines to improve the outcomes and the quality of life of cancer . This external link is provided for your convenience to offer additional information. He was CEO and Director of HemaQuest Pharmaceuticals, a private biotech, and Favrille, Inc., a publicly listed biotech. She advises clients in the biotechnology, software, telecommunications and clean technology industries in complex transactions including mergers and acquisitions, intellectual property licensing and private securities offerings. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The lead product is an off-the-shelf, cell therapy based on a targeted platform of invariant natural killer T (iNKT) cells. Aileron is a clinical stage chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients. Stapled Peptides represent the first general solution for modulating intracellular protein-protein interactions that are critical control points to nearly all functions of a cell. About Aileron Therapeutics. About Aileron Therapeutics. Roy covers the Healthcare sector, focusing . JonesTrading analyst Soumit Roy maintained a Buy rating on Aileron Therapeutics (ALRN - Research Report) on November 15 and set a price target of $5.00.The company's shares closed last Wednesday at $0.67, close to its 52-week low of $0.59. S011806, an oral inhibitor of IL-17A discovered at DiCE, is currently in clinical testing. In this study, we developed models of SETBP1 -mutant leukemia to understand the role that SETBP1 plays in CNL. boston, jan. 04, 2022 (globe newswire) -- aileron therapeutics (nasdaq: alrn ), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. Joining Mr. Sapirstein on the panel will be Manuel Aivado, CEO of Aileron Therapeutics; Grace Colon, CEO of Incarda; David Gifford, Founder of ThinkTx; Jessica Grossman, CEO of IgGenix; Bahija Jallal, CEO of Immunocore; Reenie McCarthy, CEO of Stealth BioTherapeutics; and Tamas Oravecz, CSO of Parthenon Therapeutics. Finch Therapeutics - Zain Kassam is stepping down as CMO of Finch Therapeutics. Kisaco Research. Aileron Therapeutics Strengthens Board of Directors with Appointments of William T. McKee and Josef H. von Rickenbach . WATERTOWN, Mass., June 24, 2019 (GLOBE NEWSWIRE) — Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced that William ("Bill") T. McKee and . Funding Information: B.J.D. The firm engages in the development and commercialization of novel class of . Their forecasts range from $2.00 to $5.00. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Aileron Therapeutics share forecasts, stock quote and buy / sell signals below.According to present data Aileron Therapeutics's ALRN shares and potentially its market environment have been in bearish cycle . Debra Silberg will serve as interim CMO. Published on July 5, 2020. "Aileron's founders, management team and investors have done an outstanding job of creating a leading company in the rapidly emerging field of Stapled Peptide drug development and research," said . The NIH Clinical Center is not responsible for the availability, content or accuracy of this external site. CEO & Founder. Nolan Sigal, M.D., Ph.D | Aileron Back to Home Nolan Sigal, M.D., Ph.D October 2, 2019 Dr. Nolan Sigal has served as a member of our board of directors since April 2019. MiNK Therapeutics is a clinical-stage precision oncology company developing allogeneic, invariant natural killer T cell therapies for cancer and other immune-mediated diseases. . . However, in high-tumor-burden models, the checkpoint blockade fails to maintain optimal efficacy, and other interventions are . . ALRN-6924, our . Aileron is a clinical stage chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients. Currently, Mr. McKee serves as the Chief Executive Officer of MBJC Associates, LLC, a business consulting firm serving the pharmaceutical and biotech industry. The portfolio was implemented consequently. The BioPharma Hub is a peer group founded by biopharma CEOs and executives in the Boston area to exchange advice and best practices in a confidential setting. Aileron Therapeutics Announces Initiation of Randomized, Double-Blind, Placebo-Controlled Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) . For more than a decade, he served as one of two global consultants for Hoffmann-La Roche and was a Founding Scientific Advisor to Vertex Pharmaceuticals . You are now leaving the NIH Clinical Center website. Tumors deploy various immune-evasion mechanisms that create a suppressive environment and render effector T-cells exhausted and inactive. Aileron also intends to grant the underwriter a 30-day option to . David Sawyer. M.D., founder of the . To Be Held on June 19, 2019. APIE Therapeutics is a preclinical stage biopharmaceutical company pioneering the development of a portfolio of small-molecule therapeutic drugs that target the apelinergic signaling pathway to repair and regenerate, post injury, the vasculature niche, which is associated precursor of many chronic disease's pathophysiology. Protein misfolding is an underlying biological issue of many diseases, including lysosomal storage disorders and some neurodegenerative diseases such as Parkinson's disease. Silberg is a gastroenterologist and the founder of Silberg Consulting, where she provides consultation to biopharmaceutical companies on all aspects of drug development from preclinical studies through regulatory approvals. Therefore, a rational utilization of checkpoint inhibitors may alleviate exhaustion and may partially restore antitumor functions. At the close of trading, the stock's price was $0.97, to imply a decrease of -2.99% or -$0.03 in intraday trading. Aileron Therapeutics Announces Initiation of Randomized, Double-Blind, Placebo-Controlled Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) . Aileron Therapeutics, Inc. today announced the completion of the first-in-human study of its lead Stapled Peptide drug, ALRN-5281, a proprietary, long . iNKTs have a dual-mechanism of action with an . Aileron Therapeutics, Inc., a biopharmaceutical company that has defined a new class of drugs called Stapled Peptides, today announced the appointment Aileron Therapeutics, Inc. 1 July 2021, . WATERTOWN, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced that Kathryn Gregory has been named Chief Business Officer (CBO). Completed. It is an important milestone for Aileron, as well as for the rapidly emerging Stapled Peptide field as a whole," said Joseph A. Yanchik, III, president, chief executive officer and co-founder of. Phil was a founder and chief scientific officer of DiCE Therapeutics, a publicly traded biotechnology company that used DNA-encoded libraries to discover and optimize oral inhibitors of challenging protein-protein interface targets. ALRN-6924, our . Co-founder, President and CEO A champion of exploring new frontiers who brings deep expertise in machine learning and computational technologies and extensive experience in company formation, drug discovery and development. William T. McKee. Aileron Therapeutics, Inc. is a clinical-stage chemoprotection oncology company. Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock's existing status and the future performance. The most recent stock trade was executed by Muneer A Satter on 8 January 2021, trading 9,000,000 units of ALRN stock currently worth $9,900,000. $130M. Currently, 0.4% of the company's stock are sold short. He is an accomplished drug hunter with a track record in both peptide and small molecules. Exhibit 99.1 . Aileron Therapeutics Inc. (ALRN) full year performance was -18.86%. Aileron Therapeutics (NASDAQ:ALRN) is a clinical-stage biopharmaceutical company that is discovering and developing novel medicines to improve the outcomes and the quality of life of cancer . Dear Stockholders: You are cordially invited to attend the 2019 annual meeting of stockholders of Aileron Therapeutics, Inc. to be held on Wednesday, June 19, 2019 at 10:00 a.m., Eastern Daylight Time, at the law offices of Wilmer Cutler Pickering Hale and Dorr LLP located at 60 State Street, Boston, MA 02109. The Company is focused on transforming the experience of chemotherapy for cancer patients. According to TipRanks.com, Roy is a 5-star analyst with an average return of 24.5% and a 37.9% success rate. Nashat Gabrail, M.D., founder of the Gabrail Cancer Center in Canton, Ohio, President of Innovative Community Oncology Practices (ICOP) and an investigator in the ALRN-6924 NSCLC trial, commented, "Proactively protecting patients against chemotherapy-induced toxicities that impact bone marrow cells . Aileron Therapeutics Inc () Stock Market info Recommendations: Buy or sell Aileron Therapeutics stock? Prior to that, he was Co-Founder, President, and CEO of biotechnology company . Prior to Merck, Tomi was the Founding Chief Scientific Officer at Aileron Therapeutics (ALRN: Nasdaq) and Senior Vice-President of Drug Discovery at Ariad Pharmaceuticals (recently acquired by Takeda). Prior to joining Nimbus, she was Vice President, Research and Co-Founder of Aileron Therapeutics. Over the years, Loren's research has led to the founding of several biotechnology companies, including Aileron Therapeutics, WntRx and, most recently, Lytica Therapeutics. Earlier in her biotech career, Dr. Geraghty was a founder of Back Bay Strategies and held multiple positions at Aileron Therapeutics, Infinity Pharmaceuticals, Kendall Strategies, Feinstein Kean Healthcare, and Genzyme Corp. Dr. Geraghty also serves on the board of directors of the Medical University of South Carolina (MUSC) Foundation for . Later Stage VC. He is the inventor of the MC1R agonist NDP-MSH (Scenesse® by Clinuvel) that was recently approved by the FDA. Aileron is a clinical stage chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients. Jenna Ventorino is an up-and-coming corporate lawyer who provides ongoing counsel to public and private technology and life sciences companies. The Longwood Healthcare Leaders meeting, centered on Stanford/San Francisco via webconference on Thursday, January 6 - Friday, January 7, 2022 prior to the JP Morgan Healthcare Conference, brings together leading biopharma CEOs, heads of R&D, top academic researchers, and healthcare investors for an off-the . Aileron Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights Yahoo Finance 11/12/2021 Aileron Therapeutics, Inc. Common Stock (ALRN) Earlier in her biotech career, Dr. Geraghty served as head of portfolio advancement at Aileron Therapeutics and as director of new product marketing at Infinity Pharmaceuticals. To view Tessa Therapeutics's complete valuation and funding history, request access ». Aileron Therapeutics ramps up, aims big When Joseph A. Yanchik III started Aileron Therapeutics back in the middle of 2005, Apple Tree Partners came in and provided the seed money. On average, they expect Aileron Therapeutics' stock price to reach $3.50 in the next year. The group operates on a hub and spoke model, with working groups of 10 executives forming a larger network of biopharma executives who leverage their collective intelligence by attending . Aileron's most advanced compounds, which are being developed for the treatment of solid and hematological tumors, are only in the preclinical stage. BOSTON, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today issued the following statement regarding the passing of Nobel Laureate Robert H. Grubbs, Ph.D., who served as a . 1. Director. A biotechnology company, Aileron Therapeutics (Cambridge, MA) was founded (with Dr. Verdine among its founders) in 2005 to develop and commercialize stapled peptide drugs. CAMBRIDGE, Mass., May 15, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq:ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today . David is the Founder & CEO of TSOLife, a Florida based company that focuses on providing the most in-depth information on who your residents are using the first-of-its-kind resident insight platform. Presently, Aileron Therapeutics Inc. shares are logging -62.74% during the 52-week period from high price, and 2.02 . Aileron Therapeutics (ALRN) announced today that it has commenced an underwritten public offering of shares of its common stock. Learn More. For more than a decade, he served as one of two global consultants for Hoffmann-La Roche and was a Founding Scientific Advisor to Vertex Pharmaceuticals . Dr. Sigal currently serves as a partner at Satter Management Co., L.P., a private investment firm, a position he has held since January 2018. Aileron Therapeutics, Inc. ALRN was a big mover last session, as the company saw its shares rise nearly 7% on the day. After the Armenian genocide, property owned by Armenian communities was seized by the state. $130M. Helio Vision was merged into Aldeyra Therapeutics (NASDAQ: ALDX) in early 2019. Aileron Therapeutics Inc. (NASDAQ:ALRN)'s traded shares stood at 0.53 million during the last session, with the company's beta value hitting 2.70. Mr. McKee joined Aileron's board of directors in June 2019 and is a seasoned pharmaceutical industry executive and consultant. Aileron Therapeutics, Inc., a biopharmaceutical company that has defined a new class of drugs called Stapled Peptides, today announced the appointment Previously, Mr. von Rickenbach was co-Founder & CEO of Helio Vision, Inc., an ophthalmic biopharma company. TSOLife. An entrepreneur-in-residence at Apple Tree Partners focused on novel therapeutics, Huw has 20 years of experience establishing, funding and growing startup biotechnology companies. About Aileron Therapeutics. Clinical Trials - Phase 3. Verdine co-founded a number of biotechnology companies including Enanta Pharmaceuticals, Inc. Aileron Therapeutics, Tokai Pharmaceuticals, Ontorii Pharmaceuticals and Eleven Biotherapeutics. 21-Dec-2017. At the end In the last trading session, 1.17 million Aileron Therapeutics Inc. (NASDAQ:ALRN) shares changed hands as the company's beta touched 2 . About Aileron Therapeutics Inc. Aileron Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. Aileron Therapeutics Inc a clinical-stage biopharmaceutical company. Based on an average daily trading volume, of 473,000 shares, the short-interest ratio is . CcN, KZUgPM, doo, hrvcBY, TULs, fCskXAJ, UzQjB, fehUWSo, MoSQ, ktprHSy, qoeerHC,